Jonathan I Silverberg1, Joel M Gelfand2, David J Margolis2, Mark Boguniewicz3, Luz Fonacier4, Mitchell H Grayson5, Eric L Simpson6, Peck Y Ong7, Zelma C Chiesa Fuxench2. 1. Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: JonathanISilverberg@gmail.com. 2. University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 3. National Jewish Health and University of Colorado School of Medicine, Denver, Colorado. 4. NYU Winthrop Hospital, Mineola, New York. 5. Nationwide Children's Hospital-The Ohio State University College of Medicine, Columbus, Ohio. 6. Oregon Health & Science University, Portland, Oregon. 7. Children's Hospital Los Angeles, University of Southern California, Keck School of Medicine, Los Angeles, California.
Abstract
BACKGROUND: The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in the United States population is not well established. OBJECTIVE: To elucidate the patient burden of AD in the US population. METHODS: A cross-sectional, population-based study of 602 adults was performed. Atopic dermatitis was determined using modified UK Diagnostic Criteria for AD. Its severity was assessed using self-reported global AD severity, Patient-Oriented Eczema Measure (POEM), Patient-Oriented Scoring AD (PO-SCORAD), PO-SCORAD-itch, and sleep. Quality of life was assessed using short-form (SF-)12 mental and physical health scores and Dermatology Life Quality Index (DLQI). RESULTS: Adults with AD reported higher proportions of having only fair/poor overall health (25.8% vs. 15.8%), being somewhat/very dissatisfied with life (16.7% vs 11.4%), lower weighted mean (standard deviation [SD]) SF-12 mental (45.9 [9.9] vs 50.9 [9.2]) and physical health subscores (53.0 [2.5] vs 53.5 [2.3]) and higher DLQI (4.9 [6.5] vs 1.1 [2.8]). In multivariable regression models adjusting for sociodemographics and multiple comorbid health disorders, significant stepwise decreases by AD severity (self-reported, POEM, PO-SCORAD) of overall health, life satisfaction, SF-12 mental health, and increases of DLQI scores were seen. The SF-12 physical health scores were only associated with moderate AD. Concurrently, severe PO-SCORAD, POEM, or PO-SCORAD-itch was associated with very low mean SF-12 mental health (34.7) and high DLQI scores (24.7). Atopic dermatitis commonly limited lifestyle (51.3%), led to avoidance of social interaction (39.1%), and impacted activities (43.3%). The most burdensome AD symptoms were itch (54.4%), excessive dryness/scaling (19.6%), and red/inflamed skin (7.2%). CONCLUSION: These data support the heavy burden that AD places on patients, particularly those with moderate and severe AD.
BACKGROUND: The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in the United States population is not well established. OBJECTIVE: To elucidate the patient burden of AD in the US population. METHODS: A cross-sectional, population-based study of 602 adults was performed. Atopic dermatitis was determined using modified UK Diagnostic Criteria for AD. Its severity was assessed using self-reported global AD severity, Patient-Oriented Eczema Measure (POEM), Patient-Oriented Scoring AD (PO-SCORAD), PO-SCORAD-itch, and sleep. Quality of life was assessed using short-form (SF-)12 mental and physical health scores and Dermatology Life Quality Index (DLQI). RESULTS: Adults with AD reported higher proportions of having only fair/poor overall health (25.8% vs. 15.8%), being somewhat/very dissatisfied with life (16.7% vs 11.4%), lower weighted mean (standard deviation [SD]) SF-12 mental (45.9 [9.9] vs 50.9 [9.2]) and physical health subscores (53.0 [2.5] vs 53.5 [2.3]) and higher DLQI (4.9 [6.5] vs 1.1 [2.8]). In multivariable regression models adjusting for sociodemographics and multiple comorbid health disorders, significant stepwise decreases by AD severity (self-reported, POEM, PO-SCORAD) of overall health, life satisfaction, SF-12 mental health, and increases of DLQI scores were seen. The SF-12 physical health scores were only associated with moderate AD. Concurrently, severe PO-SCORAD, POEM, or PO-SCORAD-itch was associated with very low mean SF-12 mental health (34.7) and high DLQI scores (24.7). Atopic dermatitis commonly limited lifestyle (51.3%), led to avoidance of social interaction (39.1%), and impacted activities (43.3%). The most burdensome AD symptoms were itch (54.4%), excessive dryness/scaling (19.6%), and red/inflamed skin (7.2%). CONCLUSION: These data support the heavy burden that AD places on patients, particularly those with moderate and severe AD.
Authors: K R Patel; V Singam; P P Vakharia; R Chopra; R Sacotte; N Patel; S Immaneni; R Kantor; D Y Hsu; J I Silverberg Journal: Br J Dermatol Date: 2018-11-12 Impact factor: 9.302
Authors: Rachel L Fulton; Nandita Mitra; Zelma Chiesa-Fuxench; Patrick G Sockler; David J Margolis Journal: Arch Dermatol Res Date: 2021-06-03 Impact factor: 3.017
Authors: David J Margolis; Nandita Mitra; Brian S Kim; Jamie L Duke; Ron A Berna; Ole J Hoffstad; Jenna R Wasserman; Deborah A Ferriola; Tim L Mosbruger; Bradley S Wubbenhorst; Kathrine L Nathanson; Dimitri S Monos Journal: J Immunol Date: 2021-04-16 Impact factor: 5.422
Authors: J I Silverberg; D Lei; M Yousaf; S R Janmohamed; P P Vakharia; R Chopra; R Chavda; S Gabriel; K R Patel; V Singam; R Kantor; D Y Hsu Journal: Br J Dermatol Date: 2020-09-21 Impact factor: 9.302
Authors: Christopher H Arehart; Michelle Daya; Monica Campbell; Meher Preethi Boorgula; Nicholas Rafaels; Sameer Chavan; Gloria David; Jon Hanifin; Mark K Slifka; Richard L Gallo; Tissa Hata; Lynda C Schneider; Amy S Paller; Peck Y Ong; Jonathan M Spergel; Emma Guttman-Yassky; Donald Y M Leung; Lisa A Beck; Christopher R Gignoux; Rasika A Mathias; Kathleen C Barnes Journal: J Allergy Clin Immunol Date: 2021-06-07 Impact factor: 10.793